Covidien (NYSE: COV) announces the global launch of the V-Loc™ 90 device, expanding its family of V-Loc™ absorbable wound closure devices. This latest addition to Covidien’s knotless wound closure product line received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on May 11, 2010.
According to the company, the V-Loc 90 device builds on the V-Loc™ 180 device, launched in October 2009, as the first surgical device of its kind to feature uni-directional barbed technology. The device features:
- A unique and proprietary self-anchoring loop and barb combination enables surgeons to close dermal wounds quickly and securely without tying knots or changing standard closure techniques.
- Faster absorbing material, based on Covidien’s Biosyn™ suture technology, and absorption is essentially complete within 90 to110 days.
- Usability for dermal and laparoscopic applications where a shorter absorption time is needed or preferred, such as in plastic reconstructive surgery, gynecologic surgery and general surgery.
For more information, visit www.covidien.com